美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

YARROW BIOSCIENCE, INC.

27.01

-1.4300-5.03%

盤後：27.010.00000.00%19:30 EDT

成交量：136.49萬

成交額：3,666.33萬

市值：7,211.13萬

市盈率：-1.24

高：27.49

開：26.60

低：26.00

收：28.44

52周最高：46.95

52周最低：14.68

股本：266.98萬

流通股本：160.51萬

量比：39.11

換手率：85.03%

股息：- -

股息率：- -

每股收益(TTM):-21.8600

每股收益(LYR):-66.8179

淨資產收益率：--

總資產收益率：--

市淨率：-1.02

市盈率(LYR):-0.40

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

YARROW BIOSCIENCE, INC.

交易所：

NASDAQ

成立時間：

2025

員工人數：

7

公司地址：

40 10 th Avenue,Floor 7,New York,New York,United States

官網：

http://www.yarrowbioscience.com

郵編：

10014

電話：

- -

傳真：

- -

簡介：

Yarrow Bioscience, Inc.於2011年10月作為特拉華州的一家公司註冊成立。該公司是一家臨床階段的生物製藥公司，專註於開發差異化療法，以治療存在高度未滿足醫療需求的炎症性和免疫介導性疾病。Yarrow的專有BET抑製劑（構成其InhiBET平台）旨在通過利用替代給藥途徑和增強選擇性來克服早期BET抑製劑的局限性。該公司也專註於開發自身免疫性甲狀腺疾病的療法，包括一種潛在的首創抗促甲狀腺激素受體單克隆抗體，該抗體旨在直接破壞格雷夫斯病和甲狀腺眼病的中心機制。

董事

名稱

職位

Bill Lundberg

Chairman of the Board and Director

Rebecca Frey

Chief Executive Officer and Director and President

Mona Ashiya

Director

Peter Silverman

Director

Steven Hoerter

Director

William White

Director

股東

名稱

職位

Rebecca Frey

Chief Executive Officer and Director and President

Rachael Alford

Chief Operating Officer

Tyler Zeronda

Chief Financial Officer

Lori Payton

Chief Development Officer

Steven Ryder

Chief Medical Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/YARW/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"YARW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YARW\",,,,,undefined,":{"symbol":"YARW","market":"US","secType":"STK","nameCN":"YARROW BIOSCIENCE, INC.","latestPrice":27.01,"timestamp":1789156800000,"preClose":28.44,"halted":0,"volume":1364922,"hourTrading":{"tag":"盘后","latestPrice":27.01,"preClose":27.01,"latestTime":"19:30 EDT","volume":5634,"amount":152112.82,"timestamp":1789169404854,"change":0,"changeRate":0,"amplitude":0.007405},"delay":0,"changeRate":-0.05028129395218001,"floatShares":1605140,"shares":2669800,"eps":-21.86,"marketStatus":"休市中","change":-1.43,"latestTime":"09-11 16:00:00 EDT","open":26.6,"high":27.49,"low":26,"amount":36663253.102242,"amplitude":0.052391,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-21.86,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":28.44,"preHourTrading":{"tag":"盘前","latestPrice":26.61,"preClose":28.44,"latestTime":"09:29 EDT","volume":58438,"amount":1579672.1148579998,"timestamp":1789133369124,"change":-1.83,"changeRate":-0.064346,"amplitude":0.042089},"postHourTrading":{"tag":"盘后","latestPrice":27.01,"preClose":27.01,"latestTime":"19:30 EDT","volume":5634,"amount":152112.82,"timestamp":1789169404854,"change":0,"changeRate":0,"amplitude":0.007405},"volumeRatio":39.108616320549224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"YARW\",,,,,undefined,":{"symbol":"YARW","floatShares":1605140,"roa":"--","roe":"--","lyrEps":-66.817882,"volumeRatio":39.108616320549224,"shares":2669800,"dividePrice":0,"high":27.49,"amplitude":0.052391,"preClose":28.44,"low":26,"week52Low":14.675,"pbRate":"-1.02","week52High":46.95,"institutionHeld":0,"latestPrice":27.01,"eps":-21.86,"divideRate":0,"volume":1364922,"delay":0,"ttmEps":-21.86,"open":26.6,"prevYearClose":29.005,"prevWeekClose":30.21,"prevMonthClose":32.96,"prevQuarterClose":32.535,"fiveDayClose":28.85,"twentyDayClose":42.72,"sixtyDayClose":31.645},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/YARW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"YARW","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-2.14},{"market":"US","date":"2026-07-27","symbol":"YARW","defaultRemindTime":1785159000000,"type":"split","dateTimestamp":1785124800000,"forFactor":50,"toFactor":1,"ratio":50},{"date":"2026-07-24","symbol":"YARW","amount":0.40242,"announcedDate":"2026-07-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-22","defaultRemindTime":1784899800000,"name":"VYNE Therapeutics Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-22","currency":"USD","dateTimestamp":1784865600000,"payDate":"2026-07-23"},{"market":"US","date":"2026-05-15","symbol":"YARW","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.08},{"date":"2026-02-27","symbol":"YARW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772182800000,"name":null,"time":"盤前","dateTimestamp":1772168400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"YARW\",market:\"US\",,,undefined,":[{"executeDate":"2026-07-24","recordDate":"2026-07-22","paymentDate":"2026-07-23","value":0.40242,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"YARW\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/YARW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"YARW","date":"2026-09-11","current":-1.23559,"percent":1,"low":-0.423388,"twenty":-0.411162,"median":-0.381829,"eighty":-0.296963,"high":-0.280418,"avg":-0.363867,"sd":0.051648,"marketCap":79632000},"quantilePoints":[{"date":"2026-08-14","current":-0.421219,"twenty":-0.422047,"median":-0.421219,"eighty":-0.412759,"marketCap":119616000},{"date":"2026-08-21","current":-0.376652,"twenty":-0.421318,"median":-0.411606,"eighty":-0.406626,"marketCap":106960000},{"date":"2026-08-28","current":-0.37468,"twenty":-0.419405,"median":-0.408204,"eighty":-0.384934,"marketCap":106400000},{"date":"2026-09-04","current":-0.284461,"twenty":-0.414849,"median":-0.390135,"eighty":-0.352317,"marketCap":80780000},{"date":"2026-09-11","current":-0.280418,"twenty":-0.411162,"median":-0.381829,"eighty":-0.296963,"marketCap":79632000}],"updateTime":1789238554903},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1974571740,"yearFounded":2025,"employeeNum":7,"address":"40 10 th Avenue,Floor 7,New York,New York,United States","zipCode":"10014","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.yarrowbioscience.com","stockEarnings":[{"period":"1week","weight":-0.1059},{"period":"1month","weight":-0.3685},{"period":"3month","weight":-0.167},{"period":"6month","weight":-0.0864},{"period":"1year","weight":0.7111},{"period":"ytd","weight":-0.0688}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Yarrow Bioscience, Inc.於2011年10月作為特拉華州的一家公司註冊成立。該公司是一家臨床階段的生物製藥公司，專註於開發差異化療法，以治療存在高度未滿足醫療需求的炎症性和免疫介導性疾病。Yarrow的專有BET抑製劑（構成其InhiBET平台）旨在通過利用替代給藥途徑和增強選擇性來克服早期BET抑製劑的局限性。該公司也專註於開發自身免疫性甲狀腺疾病的療法，包括一種潛在的首創抗促甲狀腺激素受體單克隆抗體，該抗體旨在直接破壞格雷夫斯病和甲狀腺眼病的中心機制。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.037101},{"month":2,"riseRate":0.444444,"avgChangeRate":0.014686},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.004341},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.154087},{"month":5,"riseRate":0.555556,"avgChangeRate":0.00572},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.050475},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.128315},{"month":8,"riseRate":0.111111,"avgChangeRate":-0.082719},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.040638},{"month":10,"riseRate":0.5,"avgChangeRate":0.011012},{"month":11,"riseRate":0.5,"avgChangeRate":-0.029442},{"month":12,"riseRate":0.375,"avgChangeRate":-0.029662}],"exchange":"NASDAQ","name":"YARROW BIOSCIENCE, INC.","nameEN":"YARROW BIOSCIENCE, INC."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"YARW\",market:\"US\",,,undefined,":{"directors":[{"name":"Bill Lundberg","position":"Chairman of the Board and Director"},{"name":"Rebecca Frey","position":"Chief Executive Officer and Director and President"},{"name":"Mona Ashiya","position":"Director"},{"name":"Peter Silverman","position":"Director"},{"name":"Steven Hoerter","position":"Director"},{"name":"William White","position":"Director"}],"executives":[{"name":"Rebecca Frey","position":"Chief Executive Officer and Director and President"},{"name":"Rachael Alford","position":"Chief Operating Officer"},{"name":"Tyler Zeronda","position":"Chief Financial Officer"},{"name":"Lori Payton","position":"Chief Development Officer"},{"name":"Steven Ryder","position":"Chief Medical Officer"}]}}}